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Background: While the pace of commissioning of new charged particle radiation therapy facilities is accelerating
worldwide, biological data pertaining to chordomas, theoretically and clinically optimally suited targets for particle
radiotherapy, are still lacking. In spite of the numerous clinical reports of successful treatment of these malignancies
with this modality, the characterization of this malignancy remains hampered by its characteristic slow cell growth,
particularly in vitro.
Methods: Cellular lethality of U-CH1-N cells in response to different qualities of radiation was compared with
immediate plating after radiation or as previously reported using the multilayered OptiCell™ system. The OptiCell™
system was used to evaluate cellular lethality over a broad dose-depth deposition range of particle radiation to
anatomically mimic the clinical setting. Cells were irradiated with either 290 MeV/n accelerated carbon ions or
70 MeV accelerated protons and photons and evaluated through colony formation assays at a single position or at
each depth, depending on the system.
Results: There was a cell killing of approximately 20–40% for all radiation qualities in the OptiCell™ system in which
chordoma cells are herein described as more radiation sensitive than regular colony formation assay. The relative
biological effectiveness values were, however, similar in both in vitro systems for any given radiation quality. Relative
biological effectiveness values of proton was 0.89, of 13–20 keV/μm carbon ions was 0.85, of 20–30 keV/μm carbon
ions was 1.27, and >30 keV/μm carbon ions was 1.69. Carbon-ions killed cells depending on both the dose and the
LET, while protons depended on the dose alone in the condition of our study. This is the first report and
characterization of a direct comparison between the effects of charged particle carbon ions versus protons for a
chordoma cell line in vitro. Our results support a potentially superior therapeutic value of carbon particle irradiation
in chordoma patients.
Conclusion: Carbon ion therapy may have an advantage for chordoma radiotherapy because of higher cell-killing
effect with high LET doses from biological observation in this study.
Keywords: Particle radiotherapy, Chordoma, OptiCell™, High LET, Carbon, Proton, Bragg peak* Correspondence: Takamitsu.Kato@colostate.edu
2Department of Environmental & Radiological Health Sciences, Colorado
State University, 1618 Campus Delivery, Fort Collins, CO 80523, USA
Full list of author information is available at the end of the article
© 2013 Fujisawa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Fujisawa et al. Radiation Oncology 2013, 8:91 Page 2 of 8
http://www.ro-journal.com/content/8/1/91Introduction
In cancer therapy, the main treatment modalities are, or
include, surgery, chemotherapy and radiation therapy.
Radiation therapy has been evolving since X-rays were
discovered. More recently, intensifying efforts have been
invested in devising improved and novel radiation the-
rapy treatments based on innovative technologies and
devices [1]. While intensity modulated radiation therapy
(IMRT) and image guided radiation therapy (IGRT)
using photons are two outstanding examples of such re-
cent developments in radiation therapy [1], the most
notable instance in the field of a vastly improved thera-
peutic gain would be that derived from charged particle
radiation therapies with accelerated carbon ions or pro-
tons [1]. Accelerated carbon ions and protons have been
very successfully used for treating solid cancers primarily
due to their advantageous property of excellent physical
dose-distribution and deposition around the Bragg peak
[2,3]. Several recent clinical studies have reported that
outcomes from charged particle beam radiation therapy
yield equivalent or superior outcomes to surgical
modalities in a number of cases such as prostate, lung,
head and neck, bone and soft tissue tumors [4,5]. In
bone tumors, namely chordomas, malignancies appear
to be highly responsive to charged particle radiation
therapy which also maximally preserves adjacent organs
and their function, whereas the latter are difficult to pre-
serve through unavoidably highly invasive surgery [5-9].
Chordomas are primary malignant bone tumors that
arise from vestigial notochordal remnants and appear
more commonly in the clivus, the basilar process of the
occipital bone and the sacrum or coccyx, vertebrae at
the caudal region of the spine [10,11]. Chordomas repre-
sent only 1 to 4% of all primary malignant tumors and
among their hallmark characteristics are containment
and slower growth kinetics together with less frequent
metastases [12]. While the first-line therapy of choice
for chordoma treatment remains surgery, radiation
therapy is also used [4,13,14] because of the deeply
ensconced anatomical location of these tumors and the
severe negative quality of life issues resulting from surgi-
cal resections [6]. Radiation therapy, especially in the
case of charged particle beams involving carbon ions or
protons, has been commanding much attention of late
particularly in the treatment of bone and soft tissue sar-
comas [6,15]. Both carbon ions and protons have thus
been successfully used in the treatment of chordomas,
and their superior therapeutic outcomes have been
reported in clinical practice [4,8,15]. Notwithstanding
these remarkable advances with charged particle beam
therapies of chordoma, there remains a severe paucity of
basic biological data on this tumor cell type. Basic scien-
tific investigation into the biology of these tumors has
been hampered due to several limiting characteristics oftheir primary cell type, namely their long mean doubling
time and the lack of types corresponding cell lines [16,17].
Nonetheless, a few noteworthy cytogenetic studies de-
scribing the karyotypes and chromosomal aberrations
through multicolor fluorescence in situ hybridization and
array have been reported [18,19]. We also have previously
reported that U-CH1-N, a newly established chordoma
cell subline from U-CH1, is very sensitive to high Linear
Energy Transfer (LET) radiation involving charged parti-
cle beams such as those of carbon, neon, silicon, argon
and iron ions [16]. To date, however, the sensitivity of
chordoma tumors to carbon and protons remains ill-
defined.
In this study, we compare the relative biological effect-
iveness (RBE) of carbon ion particles to that of proton
particles in a human chordoma cell line, UCH1-N, cul-
tured in the OptiCell™ system. We previously established
and characterized this cell line de novo [16] with a
notably abridged doubling time of approximately 3 days
compared to that of the original 7 days in the originating
cell line. The OptiCell™ system is a commercially
available cell culture technology that was designed as a
unique cell culture format with respect to growing, mon-
itoring, and transporting of cells in culture [20]. These
vessels consist of an enclosed sterile cell culture chamber
with two parallel gas-permeable cell culture-treated poly-
styrene membranes. The thin profiles of these chambers
(2 mm in width) offer very specific advantages. More
detailed acquisition of biological data at each position
(LET and dose) is possible with respect to experimental
particle beam pathways.
The present study is the first to undertake and report
a direct comparison between the cell killing effects of
290 MeV/n carbon ions and 70 MeV protons in a
chordoma cell line in a clinically relevant in vitro system.
Our data lead to a description of chordomas as an even
more radiation resistant solid tumor than previously
understood, which responds significantly to carbon par-
ticle beams in an LET and dose dependent manner ra-
ther than to protons, with an enhanced RBE greater
than one. Further work will be needed to determine
whether this characterization applies to other tumor
types and beam qualities and doses. Finally, our data
suggest that estimates of cell killing in a classical cell
culture system overestimate the responsiveness of tumor
cells to all radiation qualities, particularly in the case of
protons and strongly support the heightened relevance
of carbon beam particle therapy as the optimal treat-
ment of chordoma tumors in the clinic.
Methods and materials
Cells and culture
The human chordoma cell line U-CH1 was kindly sup-
plied by the Chordoma Foundation (Greensboro, NC,
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population derived from the original U-CH1 chordoma
cells at National Institute of Radiological Sciences
(NIRS) [16]. Cells were grown in α-MEM (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% (v/v) fetal
bovine serum (Sigma, Japan) and 1% (v/v) antibiotics
and antimycotic (Invitrogen, Carlsbad, CA, USA) and
they were maintained in a tissue culture incubator at
37°C in a 100% humidified atmosphere of 5% CO2 in air.
Irradiations
Hadron irradiations were conducted at the NIRS in Chiba,
Japan. Carbon ions were accelerated to 290 MeV/n using
the Heavy Ion Medical Accelerator in Chiba (HIMAC)
and protons were accelerated to 70 MeV using the NIRS-
930 cyclotron delivery port in C-8. Dose rates for carbon
ions and protons were set at 1 Gy/min. Monoenergetic
290 MeV/n carbon ions have a LET value of 13 keV/μm
on entrance. Monoenergetic 70 MeV protons have a LET
value of 1 keV/μm on entrance. Maximum doses of car-
bon ions and protons were delivered at depths of 14 and
4 cm in water, respectively (Figure 1) [21]. X-ray irradia-
tions were performed using a TITAN irradiator at
200 kVp, 20 mA and 0.5 cm aluminum and copper filters
(Shimadzu, Japan), at a dose rate of 1 Gy/min. Gamma-
ray irradiations were carried out at a dose rate of 2.5 Gy/
min at Colorado State University (Fort Collins, CO, USA)
using a 6,000 Ci (nominal activity) 137Cesium sealed
source [Model Mark I-68A (SS0056) J.L. Shepherd, San
Fernando, CA, USA]. Irradiations were carried out at
room temperature.
Cell survival assays using OptiCell™ culture chambers
Cultured cells were trypsinized and re-suspended into
























Figure 1 Dose and LET at each depth in water. Open circles
represent relative dose of proton (70 MeV) compared to entrance,
and closed circles represent LET spectrum of proton. Open triangles
represent relative dose of carbon ions (290 MeV/n) compared to
entrance, and triangles represent LET spectrum of carbon ions.medium containing 8,000 cells was placed into each in-
dividual OptiCell™ cell culture vessel (Thermo Fisher
Scientific, Pittsburgh, PA, USA) within 3 hours prior to
irradiation. The chamber dimensions were 2 × 65 ×
150 mm with a maximum 10 ml volume capacity. All
samples were stacked in layers and arranged perpendicu-
lar to the beam paths. Immediately following radiation
at doses of 1, 2 and 3 Gy (of exposure for the first cham-
ber) with carbon and proton particle beams and of 2, 4,
6 and 8 Gy with gamma-rays, cells were incubated at
37°C in 100% humidified atmosphere of 5% CO2 in air
for 3 weeks. After this culture period, cells were washed
with 0.9% NaCl, fixed in 100% ethanol and stained with
0.1% crystal violet. Colonies containing more than 50
cells were recorded as reproductively viable surviving
cells. Cell survival assays were carried out in as many as
four independent replicates.
Cell survival assays using standard culture dishes
Exponentially growing U-CH1-N cells cultured in T12.5
flasks (Becton Dickinson, Franklin Lakes, NJ, USA) were
irradiated with 70 keV/μm of near Bragg peak carbon
ions, entrance region protons or X-rays at room
temperature, then trypsinized and plated onto 100 mm
cell culture dishes. They were kept in an incubator for
three weeks without medium change. Up to 4 replicate
experiments were conducted and after colonies were
formed, cells were fixed and stained as described above.
Statistical analysis
Data were analyzed using Prism 5™ (GraphPad, La Jolla,
CA, USA). Standard errors of the means for data were
calculated and were depicted in each figure.
Results
Cell survival versus depth in water
Cell survival assays were conducted with our stacked
OptiCell™ cell culture system, and cells irradiated with
carbon ion and proton particles. Positions of OptiCell™
chambers at each depth were altered to the depths in
water using the physical parameters determined in our
previous report [21]. Bragg peaks of each carbon and
proton beams were delivered at depths of 14 and 4 cm,
respectively (Figure 1). Survival fractions were gradually
decreased and minimized at the Bragg peaks. Survival
fraction near the Bragg peaks for carbon showed lower
survival fractions compared to those for protons
(Figure 2A-F).
Cell survival at low LET and at high LET
Cell survival in the OptiCell™ system for U-CH1-N cells
was evaluated in response to three groups of LET values
for carbon particles. LET values were assigned to 13–20,
20–30, and >30 keV/μm value ranges. Higher LETs
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Figure 2 Cell survival curves at each depth in water. Cell survival assays were conducted with stacked OptiCell™ cell culture systems,
irradiated with 290 MeV/n carbon ions: A-C and 70 MeV protons: D-F. Error bars indicate standard errors of the means from as many as four
independent experiments.
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of low LET value only. Depths in water were translated
to radiation doses by referring to physical parameters as
our previous report (Figure 1) [21]. The survival frac-
tions that correspond to the doses were then plotted
(Figure 3A-C). Cellular lethality caused by carbon ions
was found to depend on both the dose and the LET,
while in contrast, that caused by protons depended ex-
clusively on the dose in the range of LETs in our study
(1 to 10 keV/μm).
RBE values for U-CH1-N
RBE values were calculated based on the D10 values, at
doses resulting in one decade of cell killing. RBEs were
obtained from D10 values for gamma-rays divided by the
D10 for each ion particle. Carbon ions displayed the
highest RBEs in this charged particle study: LET >30 keV/
μm 290 MeV/n carbon ions had an RBE of 1.69 and lower
LET (13–20 and 20–30 keV/μm) 290 MeV/n carbon ions
showed an RBE of 0.86 and 1.27 respectively. The proton’s
RBE value was 0.89 and very similar to LET 13–20 keV/
μm carbon ions.
Cell survival and RBE in standard cell culture
Survival fractions following irradiation of U-CH1-N
were also obtained using classic cell culture dishes. Both
gamma-rays and x-rays were used for the standard pho-
ton radiation. U-CH1-N showed very similar sensitivity
to both kinds of photon radiation. Survival fractions
were shown to depend on radiation dose, decreasing asA. Photon radiation



































Figure 3 Dose response curves for proton and carbon ions. Survival fr
and 2. Cell survival curves in standard cell culture dishes are also plotted. A
described by closed circles. Standard survival assay for x-ray was described
proton, closed triangles represent OptiCell™ survival and open triangles rep
13–20 keV/μm, open circles represent LET 20–30 keV/μm, closed circles rep
triangles represent monoenergetic carbon ions LET 70 keV/μm. Error bars i
independent experiments.doses increased (Figure 3). The entrance region of
70 MeV proton cell survival curves showed similar pro-
files to those for gamma-rays and x-rays, while in con-
trast, carbon ions survival curves revealed a markedly
more sensitive response to carbon ions than to photon
radiation. The calculated RBEs based on D10 for carbon
ions and protons against gamma-rays (D10 = 4.11) and x-
rays (D10 = 4.12) in this second in vitro system were
higher than those determined in the OptiCell™ system
and were of 2.27 and 0.90, respectively.
Discussion
Chordomas grow relatively slowly in vitro and the dou-
bling time of human chordoma U-CH1 cells in vitro is
reported as 7 days [16]. Because of its characteristic ki-
netics as slow-growing, radiobiological characterization
of chordoma cells is still lacking, though many clinical
trials have been conducted and their outcomes reported
[6,16]. Recently, however, an established cell line with a
shortened doubling time of 3 days was developed with
cell cycle kinetics thereby of particular usefulness to-
wards acquiring invaluable biological information on
chordoma cell growth and sensitivity to radiation or
anti-tumor drugs in vitro [16] and ultimately, in vivo.
In the present study we chose to focus on the cell sur-
vival of chordoma cells in vitro irradiated with two very
different clinically relevant hadron beams in terms of
quality, namely carbon ions and protons, currently used
for charged particle radiation therapy in a limited num-
ber of highly specialized centers throughout the worldton 70 MeV
4 6 8
se (Gy)
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action per dose obtained by OptiCell™ was calculated from Figure 1
. photon radiation, gamma-ray survival obtained by OptiCell™ was
by closed triangles and gamma-rays was described by open circles. B.
resent standard survival. C. carbon ions, closed squares represent LET
resent LET >30 keV/μm obtained by the OptiCell™ system. Open
ndicate standard errors of the means from as many as four
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standing of chordomas and data accrual for carbon
treatments of this tumor lag far behind those for protons
in light of the much smaller number of carbon treatment
facilities worldwide. In this study, we show that exposure
to carbon ions results in cell survival fractions lower
than those for protons near the Bragg Peak. In the
OptiCell™ system, RBE values against gamma-rays were
1.69 for higher LET (>30 keV/μm) carbon ions, 0.85 for
low LET (13–20 keV/μm) carbon ions, 1.27 for low LET
(20–30 keV/μm) carbon ions, and 0.89 for the entire
range of protons (1-10 keV/μm) (Figure 3) and thereby
demonstrate a marked superiority of carbon to proton
charged particles in killing chordoma cells, explaining at
least in part carbon’s superior ability to treat tumors in
the clinic. Dose–response curves also show these differ-
ences between carbon ions and protons. While the latter
in vitro cellular determinations reflect the clinical course
of these actual chordoma tumors following carbon ver-
sus proton therapy in vivo, they do define a larger quan-
titative therapeutic differential between the two particle
beams in question.
The cell killing effectiveness of carbon ions in our
study reveals for the first time a dependency of the
chordoma cell lethality of these hadrons on both the
radiation dose and the particles’ LET values in a three-
dimensional in vitro setting [25]. The present study
extends and refines the qualitatively similar effects of
carbon ions in a standard tissue culture environment as
we have previously shown [16]. A marked novelty and
advantage of our irradiating U-CH1-N cells in stacked
OptiCell™ chambers with accelerated carbon beams is
that we concurrently include both high LET particles
with values near the Bragg peak and low LET particles
with values outside of the Bragg peak area. In this study,
we show that high LET carbon beams which are at
present used in clinical treatment [26] do indeed kill
more U-CH1-N cells than do low LET carbon particle
beams. Moreover, we show that while proton particle
beams which are considered to be of low LET also result
in a cell-kill profile which consists of both a plateau and
a Bragg peak areas, the dose response curve for
chordoma cell-kill as a function of exposure to protons
presents no significant differences when the survival data
are segregated into outside- and near-Bragg peak areas.
Thus, low LET protons and carbon are noticeably simi-
lar effective in killing chordoma cells (proton D10 = 0.89
and 13–20 keV/μm carbon ions D10 = 0.85). Cell kill data
following proton beam exposure in our study, moreover,
suggest that the effect of protons on cell kill would be
far less therapeutically controllable or modifiable than
that of a carbon beam as the former depends on the
dose of alone. From the results above, the use of carbon
ions in particle therapy of chordoma offers a distinctadvantage with respect to both effectiveness and effi-
ciency in that its therapeutic gain depends on LET and a
demonstrated higher cell killing. These tendencies con-
firm chordoma cells patterns of superior cell kill by car-
bon ions recently shown in other cell lines, namely
Chinese Hamster Ovary (CHO) cells [21] and human
salivary gland cancer HSG cells [27].
OptiCell™ tissue culture chambers are cell culture sys-
tems optimized for cell growth, culture monitoring, and
transportation. They are designed for maximizing tissue
culture incubator space in light of their narrow cross-
sectional profile and their highly specific enclosed-system
which is readily applied to edifying three-dimensional
stacks of monolayer culture systems as in vitro models for
cell [20,28]. In the present study, we devised stacked
three-dimensional in vitro OptiCel™ arrays in configura-
tions modeling in vivo clinically relevant anatomical con-
structs which we then used to determine cell survival
fractions at each depth of beam energy deposition. Thus,
development and alignment of these live-cell biological
phantoms in three dimensions along a beam path more
relevantly mimic a desired intravital geometry. To study
relative in vitro survivals at varying depths, several other
physical culture methods have been used, including Petri
dishes fixed in a particular device [29], and a “cell stack
chamber” [30]. Relative to these other specialized cell cul-
ture methods, the most advantageous feature of the
stacked OptiCell™ chamber system is the acquisition of
many more - and greater detailed - data points, with an
optimal resolution of 2 mm. Since the maximum dose of
protons accelerated to 70 MeV was delivered at a depth of
~4 cm in this study, a detailed analysis was necessary to
acquire data near the proton Bragg peak. One significant
difference between our present study protocol and previ-
ously used methods is the relative timing of cell plating
and that of irradiations. There are essentially two different
approaches to performing studies involving colony forma-
tion assays. A first strategy involves the plating cells before
exposure to drugs or radiation, while the other relies on
treating cells prior to subsequent passaging them to assess
their resulting clonogenic ability [31]. Survival fractions
are known to depend on whether plating of cells is per-
formed before or after irradiation [32,33]. In the present
study, cells were diluted and plated prior to irradiation
and maintained undisturbed for the subsequent three
weeks, which contrasts with the methodology employed
in our previously reported study [16]. In this study, cell
survival fractions following carbon or proton irradia-
tion within OptiCell™ chambers demonstrate a marked
radioresistance when compared with cells cultured in
standard tissue culture dishes (Figure 3). The survival
difference in both culturing conditions can also be
explained in part by the respective sequences of plating
and irradiation.
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therapeutically relevant in vitro comparison between the
cell killing effects of carbon ions and protons on human
chordoma tumor derived cell lines. Our data describe an
experimental setting in which we have begun to investi-
gate the superior therapeutic index of high LET carbon
charged particle beams over all other charged particle
and photon radiation modalities. We contend that use of
the OptiCell™ system provides an overall more reliable
understanding of the biology of cells within a native
in vivo chordoma tumor environment and should form
the basis of future chordoma studies.
Conclusion
Our chordoma model describes a more biologically rep-
resentative assessment of the true radiation responsive-
ness or resistance to varying radiation qualities (high
versus low LET carbon relative to protons and photons)
and doses with respect to charged particle beams at en-
ergies and at doses currently used in the clinic. Our data
for a rare and difficult to treat chordoma tumor type
indeed confirm that chordomas are exquisitely more re-
sponsive targets to carbon ion than to proton radiother-
apy from an in vitro biological standpoint, principally in
light of a unique dependency of carbon ion effects on
both LET and dose on cellular lethality.
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